Jiangsu Sinopep-Allsino Biopharmaceutical Résultats passés
Passé contrôle des critères 4/6
Jiangsu Sinopep-Allsino Biopharmaceutical has been growing earnings at an average annual rate of 32.7%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 26.6% per year. Jiangsu Sinopep-Allsino Biopharmaceutical's return on equity is 16.1%, and it has net margins of 26.7%.
Informations clés
32.7%
Taux de croissance des bénéfices
24.9%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 26.6% |
| Rendement des fonds propres | 16.1% |
| Marge nette | 26.7% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?
Sep 26
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Jun 23Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 04There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump
Mar 04Ventilation des recettes et des dépenses
Comment Jiangsu Sinopep-Allsino Biopharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 1,576 | 421 | 339 | 212 |
| 30 Jun 24 | 1,464 | 348 | 324 | 196 |
| 31 Mar 24 | 1,181 | 208 | 300 | 171 |
| 31 Dec 23 | 1,034 | 163 | 273 | 125 |
| 30 Sep 23 | 979 | 168 | 255 | 105 |
| 30 Jun 23 | 784 | 136 | 220 | 76 |
| 31 Mar 23 | 725 | 134 | 207 | 77 |
| 31 Dec 22 | 651 | 129 | 193 | 69 |
| 30 Sep 22 | 576 | 95 | 181 | 68 |
| 30 Jun 22 | 603 | 99 | 174 | 65 |
| 31 Mar 22 | 612 | 92 | 163 | 61 |
| 31 Dec 21 | 644 | 115 | 152 | 63 |
| 30 Sep 21 | 642 | 113 | 151 | 62 |
| 30 Jun 21 | 660 | 126 | 139 | 66 |
| 31 Mar 21 | 687 | 159 | 136 | 66 |
| 31 Dec 20 | 567 | 123 | 122 | 61 |
| 30 Sep 20 | 481 | 94 | 112 | 52 |
| 30 Jun 20 | 425 | 74 | 94 | 50 |
| 31 Mar 20 | 353 | 46 | 93 | 45 |
| 31 Dec 19 | 372 | 49 | 89 | 48 |
| 30 Sep 19 | 313 | 40 | 79 | 56 |
| 30 Jun 19 | 266 | 31 | 83 | 47 |
| 31 Mar 19 | 298 | 59 | 74 | 39 |
| 31 Dec 18 | 256 | 44 | 72 | 35 |
| 30 Sep 18 | 284 | 66 | 71 | 29 |
| 30 Jun 18 | 286 | 71 | 63 | 25 |
| 31 Mar 18 | 245 | 46 | 56 | 23 |
| 31 Dec 17 | 229 | 42 | 54 | 18 |
| 30 Sep 17 | 156 | -7 | 63 | 7 |
| 30 Jun 17 | 104 | -46 | 79 | 4 |
| 31 Mar 17 | 26 | -66 | 75 | 0 |
| 31 Dec 16 | 9 | -75 | 72 | 0 |
| 30 Sep 16 | 6 | -53 | 52 | 0 |
| 30 Jun 16 | 3 | -33 | 31 | 0 |
| 31 Mar 16 | 6 | -32 | 29 | 0 |
| 31 Dec 15 | 9 | -30 | 27 | 0 |
| 31 Dec 14 | 0 | -25 | 19 | 0 |
Des revenus de qualité: 688076 has a high level of non-cash earnings.
Augmentation de la marge bénéficiaire: 688076's current net profit margins (26.7%) are higher than last year (17.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 688076's earnings have grown significantly by 32.7% per year over the past 5 years.
Accélération de la croissance: 688076's earnings growth over the past year (151.4%) exceeds its 5-year average (32.7% per year).
Bénéfices par rapport au secteur d'activité: 688076 earnings growth over the past year (151.4%) exceeded the Pharmaceuticals industry -1.2%.
Rendement des fonds propres
ROE élevé: 688076's Return on Equity (16.1%) is considered low.